Current Antipsychotics. 1st ed. 2012
- 種類:
- 電子ブック
- 責任表示:
- edited by Gerhard Gross, Mark A. Geyer
- 出版情報:
- Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2012
- 著者名:
- シリーズ名:
- Handbook of Experimental Pharmacology ; 212
- ISBN:
- 9783642257612 [3642257615]
- 注記:
- Preface -- Dopaminergic dysfunction in psychotic disorders.- Role of dopamine D2 receptors for antipsychotic activity -- Dopamine receptor signaling pathways and antipsychotics -- Serotonergic mechanisms as targets for existing and novel antipsychotics -- Antipsychotics in the treatment of psychoses during development -- Weight gain and metabolic disturbances induced by antipsychotic treatments -- Medical needs in the treatment of psychotic disorders -- Antipsychotics in the treatment of bipolar disorders -- Pharmacogenomics of antipsychotics -- Drug interactions and drug monitoting of antipsychotics -- Delivery systems and dosing for antipsychotics -- Imaging as tool to investigate psychoses and antipsychotics -- Biomarkers for antipsychotic therapies -- Behavioral animal models of antipsychotic drug actions. .
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. P - ローカル注記:
- 学内専用E-BOOKS (local access only)
類似資料:
Springer Berlin Heidelberg : Imprint: Springer |
Springer US : Imprint: Springer |
Springer Berlin Heidelberg : Imprint: Springer |
Humana Press : Imprint: Humana |
Springer New York : Imprint: Springer |
9
![]() Springer Netherlands : Imprint: Springer |
Springer Berlin Heidelberg : Imprint: Springer |
Springer Netherlands : Imprint: Springer |
Springer Netherlands : Imprint: Springer |
Springer Berlin Heidelberg : Imprint: Springer |
Springer New York : Imprint: Springer |
Springer US : Imprint: Springer |